Please login to the form below

Not currently logged in

Novo’s Tresiba reduces risk of hypoglycaemia

New clinical data on the diabetes drug also shows blood glucose control benefits

Novo Nordisk headquarters 

Novo Nordisk has released new clinical data for Tresiba (insulin degludec) showing it improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in some patients.

It's the company's first 'real world data' on the value of Tresiba in clinical practice and looked across five countries - the UK, Switzerland, Sweden, Luxembourg and Germany - and 1,770 patients.

Dr Adam Robinson, consultant diabetologist, said: “Insulin degludec has already reported a robust set of clinical trial data, and with these new real world data we can say with confidence that this treatment provides both clinical and quality of life benefits to a range of patients. 

“The results are another example of how data from the real world can inform treatment decision making in clinical practice.”

The clinical benefits found included improved blood glucose control (reported by 58 physicians in 1,149 patients), improve patient quality of life (44 physicians in 602 patients) and reduced hypoglycaemic episodes (30 physicians on 512 patients).

Additionally, 41% of physicians who treated the majority of patients reported a reduction in dose when switching patients to Tresiba (51 physicians on 1,043 patients) and data showed an 18% dose reduction with patients who used Tresiba (42 physicians on 957 patients).

Further statistics from 1,079 patients showed that the average per-patient admission cost for those with inpatient severe hypoglycaemia was 24% higher than those who did not experience severe hypoglycaemia. The data also showed that inpatient severe hypoglycaemia patients had a longer duration of hospital stay and were twice as likely to die in hospital.

Gwen Hall, diabetes specialist nurse at Haslemere Health Centre in Surrey, said: "Hypoglycaemia is one of the most common complications of diabetes treatment and can have a detrimental effect on the person living with diabetes, and on their families. It is on the NHS. It remains poorly recognised as a risk of some therapies and is under-reported by people with diabetes.”

Article by
Kirstie Pickering

11th March 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...